Nonhlanhla N. Mkhize

Johannesburg, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

Journal: iScience

Published: March 10, 2026

Cervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with Chlamydia trachomatis infections.

Cervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with Chlamydia trachomatis infections.

Journal: Sexually transmitted infections

Published: January 21, 2026

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Journal: Nature communications

Published: January 06, 2026

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

Journal: bioRxiv : the preprint server for biology

Published: December 15, 2025

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

Journal: PLoS pathogens

Published: November 17, 2025

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Journal: medRxiv : the preprint server for health sciences

Published: September 29, 2025

Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages.

Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages.

Journal: Structure (London, England : 1993)

Published: September 29, 2025

BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteins.

BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteins.

Journal: bioRxiv : the preprint server for biology

Published: September 19, 2025

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2025

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.

Journal: The lancet. HIV

Published: July 11, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026